spawns
Shares of Keros Therapeutics (NASDAQ:KROS) added ~22% within the premarket on Thursday after the biotech commenced a overview course of to guage completely different strategic choices, together with a possible sale of the corporate to maximise its shareholder worth.
Concurrently, the Lexington, Massachusetts-based agency introduced
